{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:25:38Z","timestamp":1791869138630,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-024-07692-y","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T10:02:38Z","timestamp":1725444158000},"page":"2639-2646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The impact of Germany\u2019s human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances"],"prefix":"10.1007","volume":"310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9640-9884","authenticated-orcid":false,"given":"Elizabeth","family":"Goodman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-6250","authenticated-orcid":false,"given":"Miriam","family":"Reuschenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4034-3297","authenticated-orcid":false,"given":"Tammo","family":"Viering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Luzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-6969","authenticated-orcid":false,"given":"Wolfgang","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5949-5891","authenticated-orcid":false,"given":"Monika","family":"Hampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-728X","authenticated-orcid":false,"given":"Christian","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"issue":"5","key":"7692_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jaad.2015.05.040","volume":"73","author":"MZ Handler","year":"2015","unstructured":"Handler MZ et al (2015) Human papillomavirus vaccine trials and tribulations: clinical perspectives. J Am Acad Dermatol 73(5):743\u2013756","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"7692_CR2","first-page":"664","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel C et al (2017) Worldwide burden of cancer attributable to HPV by site, country and HPV type. Lancet Oncol 141(4):664\u2013670","journal-title":"Lancet Oncol"},{"issue":"6","key":"7692_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","volume":"13","author":"C de Martel","year":"2012","unstructured":"de Martel C et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13(6):607\u2013615","journal-title":"Lancet Oncol"},{"issue":"7","key":"7692_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJM199802123380703","volume":"338","author":"GY Ho","year":"1998","unstructured":"Ho GY et al (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338(7):423\u2013428","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"7692_CR5","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","volume":"32","author":"JG Baseman","year":"2005","unstructured":"Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32(Suppl 1):S16-24","journal-title":"J Clin Virol"},{"issue":"7","key":"7692_CR6","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.24116","volume":"124","author":"H De Vuyst","year":"2009","unstructured":"De Vuyst H et al (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124(7):1626\u20131636","journal-title":"Int J Cancer"},{"issue":"2","key":"7692_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jvoice.2012.10.014","volume":"27","author":"K Makiyama","year":"2013","unstructured":"Makiyama K et al (2013) Assessment of human papilloma virus infection in adult laryngeal papilloma using a screening test. J Voice 27(2):230\u2013235","journal-title":"J Voice"},{"issue":"2","key":"7692_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/hed.22953","volume":"35","author":"GI Sanchez","year":"2013","unstructured":"Sanchez GI et al (2013) Human papillomavirus genotype detection in recurrent respiratory papillomatosis (RRP) in Colombia. Head Neck 35(2):229\u2013234","journal-title":"Head Neck"},{"issue":"3","key":"7692_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijporl.2009.11.016","volume":"74","author":"RY Seedat","year":"2010","unstructured":"Seedat RY et al (2010) HPV types causing juvenile recurrent laryngeal papillomatosis in South Africa. Int J Pediatr Otorhinolaryngol 74(3):255\u2013259","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"11","key":"7692_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.mlg.000148224.83491.0f","volume":"114","author":"BJ Wiatrak","year":"2004","unstructured":"Wiatrak BJ et al (2004) Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 114(11):1\u201323","journal-title":"Laryngoscope"},{"issue":"1","key":"7692_CR11","first-page":"2","volume":"1","author":"KP Braaten","year":"2008","unstructured":"Braaten KP, Laufer MR (2008) Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol 1(1):2\u201310","journal-title":"Rev Obstet Gynecol"},{"key":"7692_CR12","unstructured":"Robert Koch-Institut (2007) Mitteilung der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) f\u00fcr M\u00e4dchen von 12 bis 17 Jahren \u2013 Empfehlung und Begr\u00fcndung. Epidemiologisches Bulletin 97\u2013106"},{"key":"7692_CR13","unstructured":"Robert Koch-Institut (2018) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut\/Stand: August 2014. Epidemiolgisches Bulletin"},{"key":"7692_CR14","unstructured":"Robert Koch-Institut (2018) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut \u2013 2018\/2019. Epidemiolgisches Bulletin 335\u2013382"},{"issue":"6","key":"7692_CR15","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.4161\/hv.28450","volume":"10","author":"S Hense","year":"2014","unstructured":"Hense S et al (2014) HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother 10(6):1729\u20131733","journal-title":"Hum Vaccin Immunother"},{"key":"7692_CR16","unstructured":"Robert Koch-Institut (2022) Impfquoten von Kinderschutzimpfungen in Deutschland \u2013 aktuelle Ergebnisse aus der RKI-Impfsurveillance. Epidemiologisches Bull. 48"},{"issue":"12","key":"7692_CR17","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1080\/14760584.2022.2129615","volume":"21","author":"WV Wang","year":"2022","unstructured":"Wang WV et al (2022) Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. Expert Rev Vaccines 21(12):1799\u20131817","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"7692_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/cid\/ciw354","volume":"63","author":"SM Garland","year":"2016","unstructured":"Garland SM et al (2016) Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis 63(4):519\u2013527","journal-title":"Clin Infect Dis"},{"issue":"3","key":"7692_CR19","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/jnci\/djt460","volume":"106","author":"B Baldur-Felskov","year":"2014","unstructured":"Baldur-Felskov B et al (2014) Early impact of human papillomavirus vaccination on cervical neoplasia\u2013nationwide follow-up of young Danish women. J Natl Cancer Inst 106(3):460","journal-title":"J Natl Cancer Inst"},{"key":"7692_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2032","volume":"346","author":"H Ali","year":"2013","unstructured":"Ali H et al (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346:f2032","journal-title":"BMJ"},{"issue":"1","key":"7692_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12879-017-2663-7","volume":"17","author":"K Thone","year":"2017","unstructured":"Thone K, Horn J, Mikolajczyk R (2017) Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine\u2014an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC Infect Dis 17(1):564","journal-title":"BMC Infect Dis"},{"issue":"1","key":"7692_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s12879-021-06139-y","volume":"21","author":"A Denecke","year":"2021","unstructured":"Denecke A et al (2021) Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis. BMC Infect Dis 21(1):634","journal-title":"BMC Infect Dis"},{"issue":"6","key":"7692_CR23","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00404-022-06548-7","volume":"306","author":"M Reuschenbach","year":"2022","unstructured":"Reuschenbach M et al (2022) Burden of CIN2+ diagnoses and conizations in women aged 18\u201345 years-a retrospective secondary data analysis of German statutory health insurance claims data. Arch Gynecol Obstet 306(6):2077\u20132092","journal-title":"Arch Gynecol Obstet"},{"issue":"8","key":"7692_CR24","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/ijc.29508","volume":"137","author":"GS Ogilvie","year":"2015","unstructured":"Ogilvie GS et al (2015) Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. Int J Cancer 137(8):1931\u20131937","journal-title":"Int J Cancer"},{"issue":"5","key":"7692_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/sextrans-2018-053751","volume":"95","author":"M Checchi","year":"2019","unstructured":"Checchi M et al (2019) Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017. Sex Transm Infect 95(5):368\u2013373","journal-title":"Sex Transm Infect"},{"issue":"5","key":"7692_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5694\/mja16.00597","volume":"206","author":"H Ali","year":"2017","unstructured":"Ali H et al (2017) Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. Med J Aust 206(5):204\u2013209","journal-title":"Med J Aust"},{"issue":"8","key":"7692_CR27","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.4161\/hv.24904","volume":"9","author":"Y Delere","year":"2013","unstructured":"Delere Y et al (2013) HPV vaccination coverage among women aged 18\u201320 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey. Hum Vaccin Immunother 9(8):1706\u20131711","journal-title":"Hum Vaccin Immunother"},{"key":"7692_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106399","volume":"144","author":"L Bruni","year":"2021","unstructured":"Bruni L et al (2021) HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019. Prev Med 144:106399","journal-title":"Prev Med"},{"issue":"1","key":"7692_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12879-020-05002-w","volume":"20","author":"M Reuschenbach","year":"2020","unstructured":"Reuschenbach M et al (2020) Burden of HPV related anogenital diseases in young women in Germany - an analysis of German statutory health insurance claims data from 2012 to 2017. BMC Infect Dis 20(1):297","journal-title":"BMC Infect Dis"},{"key":"7692_CR30","doi-asserted-by":"crossref","unstructured":"Wang WV, et al. (2022) Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. Expert Rev Vaccines. 1\u201319.","DOI":"10.1080\/14760584.2022.2129615"},{"issue":"1","key":"7692_CR31","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1186\/1471-2458-14-1248","volume":"14","author":"C Remschmidt","year":"2014","unstructured":"Remschmidt C et al (2014) Sexual behavior and factors associated with young age at first intercourse and HPV vaccine uptake among young women in Germany: implications for HPV vaccination policies. BMC Public Health 14(1):1248","journal-title":"BMC Public Health"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-024-07692-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T09:06:11Z","timestamp":1729069571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-024-07692-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["7692"],"URL":"https:\/\/doi.org\/10.1007\/s00404-024-07692-y","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EG is employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. MR and AL are full-time employees of MSD Sharp & Dohme GmbH. TV and CJ are full-time employees of Xcenda GmbH, acting as contractors of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA for the execution of this study and the writing of the manuscript. WG received personal fees from Xcenda GmbH during the conduct of the study. MH received honoraria as speaker and member of medical advisory boards from MSD Sharp & Dohme GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require ethics committee review. It used anonymized German claims data from the \u201cInstitut f\u00fcr angewandte Gesundheitsforschung Berlin\u201d (InGef) research database. The InGef research database addresses all data protection regulations in Germany. Claims data from the participating SHI are joined in a specialized trust center, anonymized, and transferred to InGef before the data are made available for research. In accordance with the \u201cGPS \u2013 Good Practice in Secondary Data Analysis\u201d (Guideline 1: Ethics), the analysis of claims data from the statutory health insurance is permitted and does not require the approval of an ethics committee. Therefore, no patient informed consent or review by an independent ethics committee or institutional review board are required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}